RxDoctor Payments Data

Ellis Gomez, MD

Family Medicine · Buffalo, NYNPI 1912991878

Payments from drug & device makers

$1,666in general payments, 2019–2025

Across 35 payments — averaging $47.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$291
  • Bayer$270
  • Dexcom, Inc.$236
  • GSK$226
  • Insulet Corporation$188
  • Amgen$125
  • plus $329 from 4 others

What the payments were for

  • Food & beverage$1,666100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,666 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$779
Medicare patients
27
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide301$298,296
JardianceEmpagliflozin316$239,436
TrulicityDulaglutide184$184,813
MounjaroTirzepatide124$124,530
EliquisApixaban97$76,105
FarxigaDapagliflozin Propanediol60$44,288
LinzessLinaclotide67$40,960
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$37,802
XifaxanRifaximin11$36,128
KerendiaFinerenone45$33,667
Tresiba Flextouch U-100Insulin Degludec67$31,565
VascepaIcosapent Ethyl59$26,745
Breo ElliptaFluticasone/Vilanterol58$24,975
JanuviaSitagliptin Phosphate28$24,731
XareltoRivaroxaban35$24,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$291$298,296301 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$226$87,166176 claims
BayerKerendia$270$33,66745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →